Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs ProShares Ultra Gold ETF (UGL) Price & Performance

AbCellera Biologics IncTrade
ProShares Ultra Gold ETFTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs ProShares Ultra Gold ETF — how do they compare? AbCellera Biologics Inc trades at $9.03 (market cap $2.85B), while ProShares Ultra Gold ETF trades at $52.19. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.

ABCLUGL
Market Cap
$2.85B
Sector
HealthLeveraged / Inverse
52-Week High
$9.76$85.62
52-Week Low
$2.78$34.37
Enterprise Value
$2.45B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

ProShares Ultra Gold ETF

UGL trades at $50.69, up 4.45% in 24 hours, with a bullish technical signal driven by moving averages. The stock shows strong momentum but faces overbought conditions with a 6-day RSI at 85.76. Recent news highlights gold's rebound potential, with analysts projecting prices toward $4,500–$5,000 per ounce, benefiting gold-related equities.

The outlook for UGL is positive amid supportive gold market dynamics, though high RSI levels suggest near-term consolidation risks. Investment appeal hinges on sustained gold strength, while exposure to commodity volatility and Fed policy shifts remain key watchpoints for shareholders.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About ProShares Ultra Gold ETF

UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.

Read more on UGL